CJC-1295 regulatory and compounding status in 2026

Where a much-searched growth-hormone peptide actually stands with the FDA — in plain English.

TL;DR

CJC-1295 is not FDA-approved for any use. The FDA placed it in Category 2 of its review for pharmacy compounding, which flags open safety questions. A 2026 HHS proposal could ease that, but only formal FDA action changes the rules. Access stays limited and clinician-gated.

What CJC-1295 regulatory status means

CJC-1295 regulatory status is best summed up in one line: not approved, and not cleared for routine compounding. CJC-1295 is a synthetic GHRH analog — a lab-made copy of growth-hormone-releasing hormone (in plain English: the body’s own “make more growth hormone” signal). It has never earned FDA approval. Its standing today comes from a compounding review, not a drug-approval decision.

How the category system works

The FDA sorts substances nominated for 503A compounding into buckets. Think of it like an airport security line with three lanes. Category 1 substances may be compounded while review continues. Category 2 substances, including CJC-1295, are flagged for significant safety concerns and set aside. Category 3 covers other pending items. The label is a status, not a final verdict.

Who asks about it

People search this topic after hearing about CJC-1295 for energy, recovery, or growth-hormone support. They usually ask a practical question: is CJC-1295 FDA-approved, and can I get it legally right now? The honest answer requires separating marketing buzz from the actual federal record.

What the research says

CJC-1295 has real but limited human data. An early clinical study reported that a single injection raised growth hormone and IGF-1 levels for several days in healthy adults (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006). That study explored pharmacology, not long-term safety. The FDA later listed CJC-1295 among peptides it did not clear for 503A compounding (FDA, 2023). Both facts can be true at once.

What to know before considering it

Regulatory status is not the same as a safety judgment for you personally. “Available from a website” is not the same as “legal and evaluated.” Any legitimate access to a compounded peptide runs through a licensed clinician and a properly licensed pharmacy, in states where that is permitted.

The Halftime POV

We track this so members do not have to parse Federal Register language themselves. Our stance is boring on purpose: follow the current rules, work only with licensed clinicians, and treat gray-market shortcuts as a risk, not a hack.

Related reading:

• Who the peptide category framework affects
• Why some peptides are still Category 2
• Category 2 and patient risk
• Sermorelin’s regulatory status

FAQ

Is CJC-1295 FDA-approved? No. CJC-1295 has never received FDA approval for any use. It has appeared in early clinical research, but that is not approval. Any compounded version is prepared by a pharmacy and is not itself FDA-approved.

What is CJC-1295 Category 2 status? It means the FDA flagged safety questions when reviewing CJC-1295 for 503A pharmacy compounding and did not clear it. Category 2 is a regulatory holding place, not an approval and not a statutory ban.

Can you still get CJC-1295 in 2026? Access is limited and depends on federal policy that is still moving. A 2026 HHS proposal could shift several peptides back toward Category 1, but only formal FDA action makes that real.

Disclaimer

As of July 2026, several peptides discussed in this article — including CJC-1295 — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.

Get updates

Want reliable updates as peptide rules change? Join the waitlist and we’ll email you when we’re live.

Sources

• U.S. Food and Drug Administration. “Bulk Drug Substances Nominated for Use in Compounding Under Section 503A.” FDA, 2023. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
• U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” FDA, 2023. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• Teichman SL, et al. “Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295.” Journal of Clinical Endocrinology & Metabolism, 2006. PMC1435783.